Transcription of Molecular Diagnostic Infectious Disease Testing
{{id}} {{{paragraph}}}
Example: dental hygienist
Molecular Diagnostic Infectious Disease Testing
Molecular Diagnostic Infectious Disease Testing Page 1 of 23 UnitedHealthcare Medicare Advantage Policy Guideline Approved 01/12/2022 Proprietary Information of UnitedHealthcare. Copyright 2022 United HealthCare Services, Inc. UnitedHealthcare Medicare Advantage Policy Guideline Molecular Diagnostic Infectious Disease Testing Guideline Number: Approval Date: January 12, 2022 Terms and Conditions Table of Contents Page Policy Summary .. 1 Applicable Codes .. 3 Questions and Answers .. 19 References .. 19 Guideline History/Revision Information .. 22 Purpose .. 23 Terms and Conditions .. 23 Policy Summary See Purpose Overview Molecular Diagnostic Testing , which includes Deoxyribonucleic Acid-(DNA) or Ribonucleic Acid-(RNA) based analysis (with or without amplification/quantification) provides sensitive, specific and timely ( , relative to that of traditional culture-based methods) identification of diverse biological entities, including microorganisms and tumors.
(Effective 05/20/2020) 0223U ; Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected (Effective 06/25/2020)
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: